Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies aimed at significantly improving the treatment of immune diseases and cancer. Headquartered in South San Francisco, California, the company was founded in 2014 with a mission to address unmet medical needs through innovative drug development.

The company's pipeline primarily focuses on immune modulator product candidates. Its lead program, soquelitinib (CPI-818), is a first-in-class, oral therapy designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), modulating immune system signaling pathways. Other key product candidates include ciforadenant (CPI-444), an oral adenosine A2A receptor antagonist, and mupadolimab (CPI-006), a humanized anti-CD73 antibody. These therapies target various conditions, including T-cell lymphomas, solid tumors, and autoimmune diseases such as atopic dermatitis.

Under the leadership of President and CEO Richard A. Miller, M.D., Corvus Pharmaceuticals has recently made notable advancements. In April 2026, the company appointed Andrew C. Chan, M.D., Ph.D., a former Senior Vice President of Research Biology at Genentech, to its Board of Directors, enhancing its scientific expertise. The company also reported its fourth-quarter and full-year 2025 financial results in March 2026 and held an investor and analyst meeting in May 2026 to discuss soquelitinib data for atopic dermatitis. Soquelitinib is currently in Phase 3 clinical trials for relapsed/refractory peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, with positive Phase 1 data for atopic dermatitis in January 2026 leading to a significant increase in stock value.